Evidence map›Paper›PMID 38163894›Full record

ArticleJournal of biomedical science2024

Nano-modified viruses prime the tumor microenvironment and promote the photodynamic virotherapy in liver cancer.

Da-Liang Ou, Zi-Xian Liao, Ivan M Kempson, Lin Li, Pan-Chyr Yang, S-Ja Tseng

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Da-Liang Ou *Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, 10051, Taiwan.
Zi-Xian Liao *Institute of Medical Science and Technology, National Sun Yat-Sen University, Kaohsiung, 80424, Taiwan.
Ivan M KempsonFuture Industries Institute, University of South Australia, Mawson Lakes, SA, 5095, Australia.
Lin LiGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, 10051, Taiwan.
Pan-Chyr YangDepartment of Internal Medicine, National Taiwan University College of Medicine, Taipei, 10051, Taiwan. pcyang@ntu.edu.tw.
S-Ja TsengGraduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, 10051, Taiwan. sjatseng@ntu.edu.tw.ORCID http://orcid.org/0000-0002-1299-7202
National Taiwan University · TWNational Sun Yat-sen University · TWNational Taiwan University of Science and Technology · TWUniversity of South Australia · AU

Funding

National Science and Technology Council 106-2314-B-002-051-MY3National Science and Technology Council 106-2314-B-002-229-MY3National Science and Technology Council 109-2314-B-002-102National Science and Technology Council 109-2314-B-002-229-MY3National Science and Technology Council 111-2628-E007-MY3National Science and Technology Council 112-2221-E-002-115National Science and Technology Council 112-2628-B-110-004-MY3
6 · The paper itself

Abstract

backgroundAs of 2020, hepatocellular carcinoma (HCC), a form of liver cancer, stood as the third most prominent contributor to global cancer-related mortality. Combining immune checkpoint inhibitors (ICI) with other therapies has shown promising results for treating unresectable HCC, offering new opportunities. Recombinant adeno-associated viral type 2 (AAV2) virotherapy has been approved for clinical use but it efficacy is stifled through systemic administration. On the other hand, iron oxide nanoparticles (ION) can be cleared via the liver and enhance macrophage polarization, promoting infiltration of CD8

methodsTo enhance the efficacy of virotherapy and promote macrophage polarization towards the M1-type in the liver, ION-AAV2 were prepared through the coupling of ION-carboxyl and AAV2-amine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC)/N-hydroxysulfosuccinimide (Sulfo-NHS). Efficacy after systemic delivery of ION-AAV2 in an orthotopic HCC model was evaluated.

resultsAfter 28 days, the tumor weight in mice treated with ION-AAV2 was significantly reduced by 0.56-fold compared to the control group. The ION-AAV2 treatment led to an approximate 1.80-fold increase in the level of tumor associated M1-type macrophages, while the number of M2-type macrophages was reduced by 0.88-fold. Moreover, a proinflammatory response increased the population of tumor-infiltrating CD8

conclusionsOur findings suggest that the conjugation of ION with AAV2 could be utilized in virotherapy while simultaneously exploiting macrophage-modulating cancer immunotherapies to effectively suppress HCC growth.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorDependovirusMiceTumor MicroenvironmentAdeno-associated virusImmune-promoting effectIron oxide nanoparticlesMacrophageOrthotopic hepatocellular carcinomaPhotodynamic virotherapy

Identifiers

PMID38163894
PMCPMC10759334
OpenAlexW4390508167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.